lncRNA Blog lncRNA Research and Industry News
Croissy-Beaubourg and Montpellier, January 20, 2014 – Theradiag (ISIN: FR0004197747, Ticker: ALTER), a company specializing in theranostics and in vitro diagnostics, has signed, through its subsidiary Prestizia, two partnership agreements for the development of theranostics assays in HIV/AIDS with the research teams of the French National Center for Scientific Research (CNRS) / Institute of Molecular Genetics of Montpellier (IGMM) and ...
Read More »
Don't Miss
- LncTarD 2.0 – an updated comprehensive database for experimentally-supported functional lncRNA–target regulations in human diseases
- PhD and Postdoctoral Opportunities in Non-Coding RNA and Cancer Research
- Diabetes-causing gene can be regulated like a rheostat
- Emerging Non-Coding RNA Therapeutics Summit
- Amaroq Therapeutics hits early milestones and makes key appointments to Scientific Advisory Board
- New findings may contribute to better diagnosis and treatment of liver cancer
- Featured lncRNA Job – Scientist – RNA Biology
- lncRNA identified as potential new diagnostic and therapeutic target for lung cancer
- RNA molecules with no apparent function represent a new therapeutic approach against fungal infection by Candida
- RNAging: An exercise-regulated long noncoding RNA counteracts muscle aging